The general and comparative efficacy and safety of duloxetine in major depressive disorder: A systematic review and meta-analysis

Drug Safety

Volumn 32, Issue 12, 2009, Pages 1159-1173

  Gartlehner, Gerald ^a,b   Thaler, Kylie ^a   Hansen, Richard A ^c   Gaynes, Bradley N ^d  

^a DANUBE UNIVERSITY KREMS   (Austria)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c University of North Carolina   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRIPTAN DERIVATIVE; VENLAFAXINE;

ACCURACY; APPETITE; ARTICLE; BODY TEMPERATURE; CLINICAL TRIAL; COCHRANE LIBRARY; COMPARATIVE STUDY; CONSTIPATION; DATA BASE; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EMBASE; EXPERIMENTAL STUDY; HALLUCINATION; HUMAN; HYPONATREMIA; INSOMNIA; LIVER TOXICITY; MAJOR DEPRESSION; MEDLINE; NAUSEA; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PSYCINFO; SEIZURE; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SUICIDE ATTEMPT; SWEATING; SYSTEMATIC REVIEW; VOMITING; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; BODY WEIGHT; DEPRESSIVE DISORDER, MAJOR; HUMANS; NAUSEA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN SYNDROME; THIOPHENES;

EID: 70449724743     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11318930-000000000-00000     Document Type: Article

References (69)

1. Murray CJLLA, editor. The global burden of disease and injury series. Vol.1. A comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 projected to 2020. Cambridge (MA): Harvard University Press, 1996
2. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005 Jun; 62 (6): 593-602 (Pubitemid 40973434)
3. Greenberg PE, Kessler RC, Birnbaum HG, et al. The eco-nomic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 2003 Dec; 64 (12): 1465-1475
4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text revision. Washington, DC: American Psychiatric Association, 2000
5. Qaseem A, Snow V, Denberg TD, et al. Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2008; 149 (10): 725-733
6. Ellis P. Australian and New Zealand clinical practice guidelines for the treatment of depression. Aust N Z J Psychiatry 2004; 38 (6): 389-407
7. Anderson IM, Ferrier IN, Baldwin RC, et al. Evidence-based guidelines for treating depressive disorders with anti-depressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 2008; 22 (4): 343-396
8. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006 Nov; 163 (11): 1905-1917
9. Gartlehner G, Hansen RA, Thieda P, et al. Comparative effectiveness of second-generation antidepressants in the phar-macologic treatment of adult depression. Comparative effectiveness review no. 7-EHC007-EF (prepared by RTI-UNC under contract no. 290-02-0016, TO #7.) Rockville (MD): Agency for Healthcare Research and Quality, 2007 [online]. Available from URL: effectivehealthcare.ahrq.gov/reports/ final.cfm [Accessed 2009 Sep 24]
10. Balk EM, Lau J, Bonis PA. Reading and critically apprais-ing systematic reviews and meta-analyses: a short primer with a focus on hepatology. J Hepatol 2005; 43 (4): 729-736
11. Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med 2001 Apr; 20 (3 Suppl.): 21-35
12. Centre for Reviews and Dissemination. Undertaking sys-tematic reviews of research on effectiveness: CRD's guidance for those carrying outorcommissioning reviews. CRD report Number 4 (2nd edition), 2001 [online]. Available from URL: http://www.york.ac.uk/inst/crd/report4.htm [Accessed 2008 Dec 2]
13. Deeks JJ, Dinnes J, D'Amico R, et al. Evaluating non-ran-domised intervention studies. Health Technol Assess 2003; 7 (27): iii-ix, 1-173
14. Gartlehner G, Hansen RA, Nissman D, et al. A simple and valid tool distinguished efficacy from effectiveness studies. J Clin Epidemiol 2006; 60 (7): 753-755
15. Hansen RA, Moore CG, Dusetzina SB, et al. Controlling for drug dose in systematic review and meta-analysis: a case study of the effect of antidepressant dose. Med Decis Making 2009 Jan 13; 29 (1): 91-102
16. Gartlehner G, Gaynes BN, Hansen RA, et al. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med 2008; 149 (10): 734-750
17. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine 60mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 2002 Nov-Dec; 36 (6): 383-390
18. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002 Apr; 63 (4): 308-315 (Pubitemid 34456358)
19. Detke MJ, Wiltse CG, Mallinckrodt CH, et al. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo-and paroxetine-controlled trial. Eur Neuropsychopharmacol 2004 Dec; 14 (6): 457-470
20. Goldstein DJ, Mallinckrodt C, Lu Y, et al. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 2002 Mar; 63 (3): 225-231
21. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004 Aug; 24 (4): 389-399
22. Nemeroff CB, Schatzberg AF, Goldstein DJ, et al. Dulox-etine for the treatment of major depressive disorder. Psychopharmacol Bull 2002; 36 (4): 106-132
23. Perahia DG, Wang F, Mallinckrodt CH, et al. Duloxetine in the treatment of major depressive disorder: a placebo-and paroxetine-controlled trial. Eur Psychiatry 2006 Sep; 21 (6): 367-378
24. Food and Drug Administration. Duloxetine prescribing in-formation [online]. Available from URL: http://www.ac cessdata.fda.gov/drugsatfda-docs/ label/2007/021427s009s 011s013lbl.pdf [Accessed, 2009 Oct 8]
25. Thase ME, Pritchett YL, Ossanna MJ, et al. Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder. J Clin Psychopharmacol 2007; 27 (6): 672-676
26. Shelton RC, Andorn AC, Mallinckrodt CH, et al. Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression. Int Clin Psychopharmacol 2007 Nov; 22 (6): 348-355
27. Brannan SK, Mallinckrodt CH, Brown EB, et al. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res 2005 Jan; 39 (1): 43-53
28. Pigott TA, Prakash A, Arnold LM, et al. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder. Curr Med Res Opin 2007 Jun; 23 (6): 1303-1318 (Pubitemid 46998440)
29. Nierenberg AA, Greist JH, Mallinckrodt CH, et al. Dulox-etine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of anti-depressant action, a non-inferiority study. Curr Med Res Opin 2007 Feb; 23 (2): 401-416
30. Perahia DG, Kajdasz DK, Walker DJ, et al. Duloxetine 60 mg once daily in the treatment of milder major depressive disorder. Int J Clin Pract 2006; 5: 613-620
31. Lindstrom E, Lewander T, Malm U, et al. Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia: clinical validation of a self-rating version of the UKU Side Effect Rating Scale (UKU-SERS-Pat). Nord J Psychiatry 2001; 55 Suppl. 44: 5-69
32. Food and Drug Administration. Guideline for industry. Clinical safety data management: definitions and standards for expedited reporting [online]. Available from URL: http://www.fda.gov/cder/guidance/iche2a.pdf [Accessed 2008 Feb 2]
33. Gartlehner G, Thieda P,Hansen RA, et al. Comparative risk for harms of second-generation antidepressants: a systematic review and meta-analysis. Drug Saf 2008; 31 (10): 851-865
34. Raskin J, Goldstein DJ, Mallinckrodt CH, et al. Duloxetine in the long-term treatment of major depressive disorder. J Clin Psychiatry 2003 Oct; 64 (10): 1237-1244
35. Acharya N, Rosen AS, Polzer JP, et al. Duloxetine: meta-analyses of suicidal behaviors and ideation in clinical trials for major depressive disorder. J Clin Psychopharmacol 2006; 26 (6): 587-594
36. Montejo AL, Llorca G, Izquierdo JA, et al. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry 2001; 62 Suppl. 3: 10-21
37. Hudson JI, Wohlreich MM, Kajdasz DK, et al. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. Human Psychopharmacol 2005; 20 (5): 327-341
38. Food and Drug Administration. FDA alert 07/2006: po-tentially life-threatening serotonin syndrome with combined use of SSRIs or SNRIs and triptans medications, 2006 [online]. Available from URL: http://www.fda.gov/ cder/drug/InfoSheets/HCP/duloxetineHCP.pdf [Accessed 2009 Jan 13]
39. Food and Drug Administration. Duloxetine statistical re-views [online]. Available from URL: http://www.accessdata. fda.gov/drugsatfda-docs/nda/2004/ 021427-s000-Cymbalta- Statr.pdf [Accessed, 2008 Dec 30]
40. Dunner DL, Wilson M, Fava M, et al. Long-term toler-ability and effectiveness of duloxetine in the treatment of major depressive disorder. Depress Anxiety 2008; 25 (5): E1-8
41. Wernicke J, Lledo A, Raskin J, et al. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies. Drug Saf 2007; 30 (5): 437-455
42. Thase ME, Tran PV, Wiltse C, et al. Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. J Clin Psychopharmacol 2005 Apr; 25 (2): 132-140
43. Khan A, Bose A, Alexopoulos GS, et al. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder. Clin Drug Investig 2007; 27 (7): 481-492
44. Wade A, Gembert K, Florea I. A comparative study of the efficacy of acute and continuation treatment with escita-lopram versus duloxetine in patients with major depressive disorder. Curr Med Res Opin 2007 Jul; 23 (7): 1605-1614
45. Lee P, Shu L, Xu X, et al. Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil. Psychiatry Clin Neurosci 2007 Jun; 61 (3): 295-307
46. Perahia DG, Pritchett YL, Kajdasz DK, et al. A random-ized, double-blind comparison of duloxetine and venla-faxine in the treatment of patients with major depressive disorder. J Psychiatr Res 2008 Jan; 42 (1): 22-34
47. Cookson J, Gilaberte I, Desaiah D, et al. Treatment benefits of duloxetine in major depressive disorder as assessed by number needed to treat. Int Clin Psychopharmacol 2006; 21 (5): 267-273
48. Mallinckrodt CH, Prakash A, Houston JP, et al. Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram). Neuropsychobiology 2007; 56 (2-3): 73-85
49. Greist J, McNamara RK, Mallinckrodt CH, et al. Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine. Clin Ther 2004 Sep; 26 (9): 1446-1455
50. Clayton A, Kornstein S, Prakash A, et al. Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder. J Sex Med 2007 Jul; 4 (4 Pt 1): 917-929 (Pubitemid 47082256)
51. Delgado PL, Brannan SK, Mallinckrodt CH, et al. Sexual functioning assessed in 4 double-blind placebo-and par-oxetine-controlled trials of duloxetine for major depressive disorder. J Clin Psychiatry 2005 Jun; 66 (6): 686-692
52. Anderson IM, Tomenson BM. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. BMJ 1995 1995 Jun 3; 310 (6992): 1433-1438
53. Montgomery SA, Henry J, McDonald G, et al. Selective ser-otonin reuptake inhibitors: meta-analysis of discontinuation rates. Int Clin Psychopharmacol 1994; 9: 47-53
54. Krebs EE, Gaynes BN, Gartlehner G, et al. Treating the physical symptoms of depression with second-generation antidepressants: a systematic review and metaanalysis. Psychosomatics 2008; 49 (3): 191-198
55. Brecht S, Courtecuisse C, Debieuvre C, et al. Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial. J Clin Psychiatry 2007 Nov; 68 (11): 1707-1716
56. Raskin J, Wiltse CG, Siegal A, et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry 2007 Jun; 164 (6): 900-909 (Pubitemid 46972905)
57. Burt VK, Wohlreich MM, Mallinckrodt CH, et al. Dulox-etine for the treatment of major depressive disorder in women ages 40 to 55 years. Psychosomatics 2005 Jul-Aug; 46 (4): 345-354
58. Raskin J, Wiltse CG, Dinkel JJ, et al. Safety and tolerability of duloxetine at 60mg once daily in elderly patients with major depressive disorder. J Clin Psychopharmacol 2008 Feb; 28 (1): 32-38
59. Russell J, Raskin J, Wiltse C, et al. Efficacy and tolerability of duloxetine treatment in elderly patients with major depressive disorder and concurrent anxiety symptoms. Psychiatry 2007; 4 (6): 33-45
60. Nelson JC, Wohlreich MM, Mallinckrodt CH, et al. Duloxetine for the treatment of major depressive disorder in older patients. Am J Geriatr Psychiatry 2005 Mar; 13 (3): 227-235
61. Wohlreich MM, Mallinckrodt CH, Watkin JG, et al. Du-loxetine for the long-term treatment of major depressive disorder in patients aged 65 and older: an open-label study. BMC Geriatr 2004 Dec 7; 4: 11
62. Wise TN, Wiltse CG, Iosifescu DV, et al. The safety and tolerability of duloxetine in depressed elderly patients with and without medical comorbidity. Int J Clin Pract 2007 Aug; 61 (8): 1283-1293
63. Lewis-Fernandez R, Blanco C, Mallinckrodt CH, et al. Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy in U.S. Hispanic and majority Caucasian patients. J Clin Psychiatry 2006; 67 (9): 1379-1390
64. Bailey RK, Mallinckrodt CH, Wohlreich MM, et al. Du-loxetine in the treatment of major depressive disorder: comparisons of safety and efficacy. J Natl Med Assoc 2006; 98 (3): 437-447
65. Stewart DE, Wohlreich MM, Mallinckrodt CH, et al. Du-loxetine in the treatment of major depressive disorder: comparisons of safety and tolerability in male and female patients. J Affect Disord 2006; 94 (1-3): 183-189
66. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation anti-depressants: a multiple-treatments meta-analysis. Lancet 2009 Feb 28; 373 (9665): 746-758
67. Gartlehner G, Hansen RA. Are some antidepressants better than others? Nat Rev Neurol 2009 May; 5 (5): 239-240
68. Mallinckrodt CH, Goldstein DJ, Detke MJ, et al. Dulox-etine: new treatment for the emotional and physical symptoms of depression. Prim Care Companion J Clin Psychiatry 2003 Feb; 5 (1): 19-28
69. Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial se-verity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008 Feb; 5 (2): e45